% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

errico51 1 post  |  Last Activity: Jan 30, 2016 3:52 AM Member since: Sep 16, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Aschoff observed, The latest data support the view that NSI-566 cells demonstrate biological activity in all three indications and could lead to clinically meaningful treatment benefits. Neuralstem also provided anticipated timing for its NSI-566 programs. Final follow up from a Phase 2 trial in ALS (n=15) was completed in December 2015, and a larger Phase 2b efficacy trial for ALS is scheduled. Every NSI-566 treated patient in Phase 2b will receive 40 cervical and lumbar injections totaling 12 million NSI-566 cells, and endpoints including ALSFRS, grip strength, and vital capacity will be measured at 9 months. Neuralstem also plans to initiate a Phase 2/3 chronic stroke trial in China in 2H16, and continue its treatment of chronic spinal cord injury in a higher dose cohort...

    Sentiment: Strong Buy

0.256-0.0034(-1.31%)Jul 22 3:59 PMEDT